FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma By Ogkologos - October 27, 2025 405 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the C-POST study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Is AI Ready to Play a Leading Role in Colorectal Cancer... October 10, 2023 Artificial Intelligence Brings Pancreatic Cancer Screening One Step Closer to Reality... July 2, 2020 Update Shows Long-Term Survival Benefit with Abemaciclib Plus Fulvestrant in HR-positive,... November 21, 2020 Following Abnormal Cancer Screening Results, Multi-Level Reminders May Increase Follow-Up December 22, 2023 Load more HOT NEWS Health inequalities: Why is it harder for some people to eat... EMA Recommends Granting Marketing Authorisation for Generic Abiraterone Acetate One Million Masks Donated! But GreaterGood Will Continue to Help Where... FDA Grants Accelerated Approval to Pembrolizumab for HER2-positive Gastric Cancer
